Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Company’s proprietary stem cell-based therapeutic for the treatment of chronic back pain caused by degenerative disc disease (DDD). The first cohort of 10 participants (8 receiving CELZ-201-DDT and 2 receiving placebo) completed the study phase without any dose-limiting toxicities or serious adverse events. Blinded preliminary data suggest encouraging therapeutic potential in alleviating back pain and restoring functionality. Following a comprehensive safety review, the independent Data Safety Monitoring Board (DSMB) recommended the trial proceed to the next cohort as planned. Key Milestones Achieved: Safety Confirmed: CELZ-201-DDT demonstrated an excellent safety profile, with no serious adverse events reported in the first cohort.Preliminary Efficacy Signals: Blinded data suggest potential therapeutic benefit in addressing chronic back pain associated with degenerative disc disease.DSMB Endorsement: The DSMB approved continuation of the study, validating the safety and integrity of the trial design.Next Steps: Enrollment for the second cohort is expected in the current first quarter of 2025, with comprehensive data from subsequent cohorts guiding future clinical and regulatory plans. “This milestone underscores our commitment to addressing chronic back pain, a debilitating condition with limited effective treatment options,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “The safety and early signals observed in this trial strengthen our belief that CELZ-201-DDT has the potential to transform the standard of care for patients suffering from degenerative disc disease.” Advancing Innovation in Regenerative MedicineCreative Medical Technology Holdings is committed to pioneering regenerative solutions that improve quality of life for patients with chronic and debilitating conditions. CELZ-201-DDT represents the Company’s dedication to leveraging stem cell technology to address the root causes of pain and degenerative conditions, providing patients with a novel, non-opioid therapeutic option. “Our progre...

More updates from Creative Medical Technology Holdings, Inc.